A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer

被引：0
|
作者：
Yasushi Sato
Hiroyuki Ohnuma
Masahiro Hirakawa
Minoru Takahashi
Takahiro Osuga
Yutaka Okagawa
Kazuyuki Murase
Kohichi Takada
Yutaka Kawano
Satoshi Iyama
Tsuyoshi Hayashi
Tsutomu Sato
Koji Miyanishi
Rishu Takimoto
Masayoshi Kobune
Kenji Okita
Toru Mizuguchi
Tomohisa Furuhata
Koichi Hirata
Junji Kato
机构：
[1] Sapporo Medical University School of Medicine,Department of Medical Oncology and Hematology
[2] Sapporo Kyoritsu Gorinbashi Hospital,Division of Gastroenterology
[3] Sapporo Medical University School of Medicine,Department of Surgery, Surgical Oncology and Science
来源：
Cancer Chemotherapy and Pharmacology | 2015年 / 75卷
关键词：
Bevacizumab; Capecitabine; Colorectal cancer; Irinotecan; Oxaliplatin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：587 / 594
页数：7
相关论文
共 50 条
  • [1] A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer
    Sato, Yasushi
    Ohnuma, Hiroyuki
    Hirakawa, Masahiro
    Takahashi, Minoru
    Osuga, Takahiro
    Okagawa, Yutaka
    Murase, Kazuyuki
    Takada, Kohichi
    Kawano, Yutaka
    Iyama, Satoshi
    Hayashi, Tsuyoshi
    Sato, Tsutomu
    Miyanishi, Koji
    Takimoto, Rishu
    Kobune, Masayoshi
    Okita, Kenji
    Mizuguchi, Toru
    Furuhata, Tomohisa
    Hirata, Koichi
    Kato, Junji
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 587 - 594
  • [2] A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab (bev) as a first-line therapy for patients with metastatic colorectal cancer
    Sato, Yasushi
    Ohnuma, Hiroyuki
    Hirakawa, Masahiro
    Takahashi, Minoru
    Osuga, Takahiro
    Takada, Kohichi
    Hayashi, Tsuyoshi
    Sato, Tsutomu
    Miyanishi, Koji
    Takimoto, Rishu
    Kobune, Masayoshi
    Okita, Kenji
    Furuhata, Tomohisa
    Hirata, Koichi
    Kato, Junji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [3] A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study
    Sato, Yasushi
    Hirakawa, Masahiro
    Ohnuma, Hiroyuki
    Takahashi, Minoru
    Okamoto, Tetsuro
    Okamoto, Koichi
    Miyamoto, Hiroshi
    Muguruma, Naoki
    Furuhata, Tomohisa
    Takemasa, Ichiro
    Kato, Junji
    Takayama, Tetsuji
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (06) : 1133 - 1139
  • [4] A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study
    Yasushi Sato
    Masahiro Hirakawa
    Hiroyuki Ohnuma
    Minoru Takahashi
    Tetsuro Okamoto
    Koichi Okamoto
    Hiroshi Miyamoto
    Naoki Muguruma
    Tomohisa Furuhata
    Ichiro Takemasa
    Junji Kato
    Tetsuji Takayama
    [J]. Cancer Chemotherapy and Pharmacology, 2017, 80 : 1133 - 1139
  • [5] A triplet combination with oxaliplatin/capecitabine/irinotecan (XELOXIRI) plus cetuximab (Cmab) as a first-line therapy in wild-type KRAS, metastatic colorectal cancer: a dose escalating study
    Sato, Y.
    Ohnuma, H.
    Hirakawa, M.
    Kikuch, S.
    Takahashi, M.
    Okamoto, T.
    Tsuji, Y.
    Okita, K.
    Furuhata, T.
    Takemasa, I.
    Kato, J.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [6] Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
    Zarate, R.
    Rodriguez, J.
    Bandres, E.
    Patino-Garcia, A.
    Ponz-Sarvise, M.
    Viudez, A.
    Ramirez, N.
    Bitarte, N.
    Chopitea, A.
    Gacia-Foncillas, J.
    [J]. BRITISH JOURNAL OF CANCER, 2010, 102 (06) : 987 - 994
  • [7] Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
    R Zarate
    J Rodríguez
    E Bandres
    A Patiño-Garcia
    M Ponz-Sarvise
    A Viudez
    N Ramirez
    N Bitarte
    A Chopitea
    J Gacía-Foncillas
    [J]. British Journal of Cancer, 2010, 102 : 987 - 994
  • [8] A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients
    Van Cutsem, E.
    Verslype, C.
    Beale, P.
    Clarke, S.
    Bugat, R.
    Rakhit, A.
    Fettner, S. H.
    Brennscheidt, U.
    Feyereislova, A.
    Feyereislova, A.
    Delord, J. -P.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (02) : 332 - 339
  • [9] A phase II study of capecitabine, oxaliplatin and irinotecan (XELOXIRI) as salvage therapy in patients with refractory metastatic colorectal cancer.
    Kwok, Gin Wai
    Leung, Roland Ching-Yu
    Chiu, Joanne
    Tang, Vikki
    Yau, Thomas Cheung
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group
    Schmiegel, W.
    Reinacher-Schick, A.
    Arnold, D.
    Kubicka, S.
    Freier, W.
    Dietrich, G.
    Geissler, M.
    Hegewisch-Becker, S.
    Tannapfel, A.
    Pohl, M.
    Hinke, A.
    Schmoll, H. J.
    Graeven, U.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (06) : 1580 - 1587
12345